Skip to main content
SpringerLink
Log in

The Authors’ Reply

  • Correspondence
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Baldessarini RJ. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis. Drug Saf 2012; 35(12): 1183

    PubMed  Google Scholar 

  2. Moteshafi H, Zhornitsky S, Brunelle S, et al. Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis. Drug Saf 2012; 35(10): 819–36

    Article  PubMed  CAS  Google Scholar 

  3. Moteshafi H, Stip E. Comparing tolerability profile of quetiapine, risperidone, aripiprazole and ziprasidone in schizophrenia and affective disorders: a meta-analysis. Expert Opin Drug Saf 2012; 11(5): 713–32

    Article  PubMed  CAS  Google Scholar 

  4. Hill AL, Sun B, Karagianis JL, et al. Dose-associated changes in safety and efficacy parameters observed in a 24-week maintenance trial of olanzapine long-acting injection in patients with schizophrenia. BMC Psychiatry 2011 Feb 15; 11: 28

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  5. Sengupta SM, Klink R, Stip E, et al. Weight gain and lipid metabolic abnormalities induced by olanzapine in first-episode, drug-naïve patients with psychotic disorders. Schizophr Res 2005 Dec 1; 80(1): 131–3

    Article  PubMed  Google Scholar 

  6. Stip E, Lungu OV, Anselmo K, et al. Neural changes associated with appetite information processing in schizophrenic patients after 16 weeks of olanzapine treatment. Transl Psychiatry 2012 Jun 19; 2: e128

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  7. Mathews J, Newcomer JW, Mathews JR, et al. Neural correlates of weight gain with olanzapine. Arch Gen Psychiatry 2012 Aug 6; 1-11

Download references

Author information

Authors and Affiliations

  1. University of Montreal, Montreal, Quebec, Canada

    Emmanuel Stip & Hoda Moteshafi

Authors
  1. Emmanuel Stip
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hoda Moteshafi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stip, E., Moteshafi, H. The Authors’ Reply. Drug Saf 35, 1183–1184 (2012). https://doi.org/10.1007/BF03262004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03262004

Keywords

Search

Navigation